Fig. 2From: Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lungProgression-free survival (PFS) outcomes in the IMA study cohort determined using Kaplan-Meier estimates. The PFS following first line chemotherapy was compared accreting to targeted therapy (Panel A), or immunotherapy (Panel B). PFS outcome following 2nd line chemotherapy was also analyzed based on immunotherapy (Panel C)Back to article page